Request a quote
All products
Active Pharmaceutical IngredientsPharmaceutical IntermediatesVeterinary APIsPharmaceutical Packaging
Quality & compliance Resources About Contact
ENESFRRU
Request a quote

Flunixin Meglumine

Flunixin meglumine salt, 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt · CAS 42461-84-7

Veterinary Veterinary grade / EP (vet) CoA per batchSDSMRL guidance note

A nicotinic acid NSAID that only becomes injectable as the meglumine salt. The salt ratio and the water content decide stability, and both are released per lot with the pH of the reconstituted solution.

Part of the veterinary anti-inflammatory line, mostly injectables where the salt form and the polymorph decide stability.

Identity

Catalogue no.BP-VET-008
CAS number42461-84-7
Molecular formulaC14H11F3N2O2 · C7H17NO5
Molecular weight491.46 g/mol
HS code2933.39
SynonymsFlunixin meglumine salt, 2-[[2-methyl-3-(trifluoromethyl)phenyl]amino]-3-pyridinecarboxylic acid meglumine salt
Product lineVeterinary APIs
CategoryVeterinary Anti-inflammatories

Release specification

Catalogue standard below. For a supply agreement we release against your dossier specification; send it with the enquiry and the CoA will be built around it.

ParameterSpecification
Assay98.5–101.0%
Related substancesAny unspecified impurity ≤ 0.30%; total impurities ≤ 1.0%
Water content≤ 0.5% (Karl Fischer)
Heavy metals≤ 20 ppm (ICP-MS)
pH (5% solution)7.5–9.0

Application

Non-narcotic analgesic and anti-inflammatory for cattle, horses and swine, mainly injectable.

Packaging, storage & logistics

Standard packaging1 kg / 5 kg aluminium-laminated foil bag in fibre drum
Minimum order10 kg
Lead time20–30 days
Storage conditionsStore below 25 °C, protected from light and humidity
Shipping documentsInvoice, packing list, CoA, SDS, certificate of origin; DGM/IATA declaration where applicable

Pack sizes available — pick one to prefill the enquiry

100 g1 kg5 kg25 kg

Documentation provided

  • CoA per batchBatch-specific, tested against the specification agreed at PO stage
  • SDSCurrent GHS revision; destination-language version on request
  • MRL guidance noteMaximum residue limit and withdrawal-period reference for the destination market

Need the DMF open part, a sample CoA or an audit pack before you can qualify us? Ask on the enquiry form — we send those documents before any commercial discussion.

Request a quotation

Submitting opens your email client with these details filled in, so the enquiry reaches gm@bioranpharma.com directly. We use your details only to answer this enquiry — see privacy & data use.

Related products